KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $942.8 million.

  • Biomarin Pharmaceutical's Cash & Equivalents rose 85.08% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 85.08%. This contributed to the annual value of $942.8 million for FY2024, which is 24.86% up from last year.
  • According to the latest figures from FY2024, Biomarin Pharmaceutical's Cash & Equivalents is $942.8 million, which was up 24.86% from $755.1 million recorded in FY2023.
  • Over the past 5 years, Biomarin Pharmaceutical's Cash & Equivalents peaked at $942.8 million during FY2024, and registered a low of $587.3 million during FY2021.
  • For the 3-year period, Biomarin Pharmaceutical's Cash & Equivalents averaged around $807.5 million, with its median value being $755.1 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 48.40% in 2020, then declined by 9.53% in 2021.
  • Biomarin Pharmaceutical's Cash & Equivalents (Yearly) stood at $649.2 million in 2020, then dropped by 9.53% to $587.3 million in 2021, then climbed by 23.37% to $724.5 million in 2022, then climbed by 4.22% to $755.1 million in 2023, then grew by 24.86% to $942.8 million in 2024.